Project

PCG-2/UCA

Aborted · 2016 until 2017

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Aborted
Start Date
2016
End Date
2017
Financing
Industry
Brief description/objective

Randomized, double-blind, double-dummy, placebo-controlled, Phase III
clinical trial on the efficacy and safety of a 12-weeks add-on treatment with
LT-02 (gastro-resistant phosphatidylcholine granules) vs. placebo in
patients with ulcerative colitis refractory to standard treatment with
mesalamine